Aegerion Pharmaceuticals Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Employees
-
200
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$153M
Aegerion Pharmaceuticals General Information
Description
Operator of a bio-pharmaceutical company designed to develop and commercialize therapies for debilitating diseases. The company's therapies specializes in hyperlipidemia and metabolic diseases by controlling high levels of fat particles in blood, enabling medical professionals to treat patients with cardiovascular and metabolic diseases.
Contact Information
Website
www.aegerion.comCorporate Office
- One Main Street
- Suite 800
- Cambridge, MA 02142
- United States
Corporate Office
- One Main Street
- Suite 800
- Cambridge, MA 02142
- United States
Aegerion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 24-Sep-2019 | $153M | Completed | Bankruptcy: Admin/Reorg | ||
| 13. Debt Refinancing | 20-May-2019 | Completed | Bankruptcy: Admin/Reorg | |||
| 12. Debt - General | 20-May-2019 | Completed | Bankruptcy: Admin/Reorg | |||
| 11. Bankruptcy: Admin/Reorg | 20-May-2019 | Completed | Bankruptcy: Admin/Reorg | |||
| 10. Debt Refinancing | 12-Nov-2018 | Completed | Profitable | |||
| 9. Debt - General | 15-Mar-2018 | Completed | Profitable | |||
| 8. Merger/Acquisition | 29-Nov-2016 | Completed | Profitable | |||
| 7. PIPE | 01-Jul-2015 | Completed | Generating Revenue | |||
| 6. Debt - General | 28-Feb-2011 | $10M | $97.8M | Completed | Clinical Trials - Phase 3 | |
| 5. IPO | 22-Oct-2010 | $47.5M | $87.8M | Completed | Clinical Trials - Phase 3 |
Aegerion Pharmaceuticals Comparisons
Industry
Financing
Details
Aegerion Pharmaceuticals Competitors (86)
One of Aegerion Pharmaceuticals’s 86 competitors is Verona Pharma, a Corporate Backed or Acquired company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
| Avammune Therapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Castle Creek Biosciences | Venture Capital-Backed | Exton, PA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA |
Aegerion Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aegerion Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aegerion Pharmaceuticals Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent International | PE/Buyout | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| Athyrium Capital Management | Asset Manager | Minority | ||
| Broadfin Capital | Hedge Fund | Minority | ||
| Index Ventures | Venture Capital | Minority |
Aegerion Pharmaceuticals Investments (1)
Aegerion Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Astrazeneca (Myalept) for . The deal was made on 12-Jan-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Astrazeneca (Myalept) | 12-Jan-2015 | Corporate Asset Purchase | Buildings and Property |
Aegerion Pharmaceuticals FAQs
-
When was Aegerion Pharmaceuticals founded?
Aegerion Pharmaceuticals was founded in 2005.
-
Where is Aegerion Pharmaceuticals headquartered?
Aegerion Pharmaceuticals is headquartered in Cambridge, MA.
-
What is the size of Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals has 200 total employees.
-
What industry is Aegerion Pharmaceuticals in?
Aegerion Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Aegerion Pharmaceuticals a private or public company?
Aegerion Pharmaceuticals is a Private company.
-
What is the current valuation of Aegerion Pharmaceuticals?
The current valuation of Aegerion Pharmaceuticals is .
-
What is Aegerion Pharmaceuticals’s current revenue?
The current revenue for Aegerion Pharmaceuticals is .
-
How much funding has Aegerion Pharmaceuticals raised over time?
Aegerion Pharmaceuticals has raised $112M.
-
Who are Aegerion Pharmaceuticals’s investors?
Advent International, Alta Partners, Athyrium Capital Management, Broadfin Capital, and Index Ventures are 5 of 11 investors who have invested in Aegerion Pharmaceuticals.
-
Who are Aegerion Pharmaceuticals’s competitors?
Verona Pharma, Lexeo Therapeutics, Avammune Therapeutics, Castle Creek Biosciences, and Immusoft are some of the 86 competitors of Aegerion Pharmaceuticals.
-
When was Aegerion Pharmaceuticals acquired?
Aegerion Pharmaceuticals was acquired on 24-Sep-2019.
-
Who acquired Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals was acquired by Amryt Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
